Work

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

Year: 2017

Type: article

Abstract: = .002) at day 30 post-HCT in vorinostat-treated subjects compared with similarly treated patients who did not receive vorinostat. Vorinostat for GVHD prevention is an effective strategy that should be confirmed in a randomized phase 3 study. This trial was registered at www.clinicaltrials.gov as #NCT01790568.

Source: Blood

DOI: 10.1182/blood-2017-06-790469

Authors: Sung Won Choi, Thomas Braun, Israel Henig, Erin Gatza, John Magenau, Brian Parkin, Attaphol Pawarode, Mary Riwes, Greg Yanik, Charles A. Dinarello, Pavan Reddy

Institutions: Michigan Medicine, University of Michigan, Radboud University Medical Center, University of Colorado Anschutz

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: G1404790370, G1762593819, Transforming Translational Science and Education to Benefit Human Health, G3696477608, University of Michigan Rogel Cancer Center Support Grant 2023-2028

OpenAlex ID: W2742489639

FWCI: 4.659

Cites: 40

Cited by: 67

Related to: 10